92 from the previous closing price of . A single-dose, intranasal vaccine candidate designed to protect against COVID-19, the disease caused by the SARS-CoV-2 virus. ALT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. · Turning out attention to how the Altimmune, Inc. With its Forward Dividend at 0 and a yield of 0%, altimmune the company’s investors could be worried for the ALT stock to lose ahead of the earnings release. If a stock is valued near, or slightly below the market average, research has shown that the market expects the stock’s dividend to increase.
83% while ALT is higher by 490. has a market cap of 5. | Nasdaq: ALT | Nasdaq. Find the latest Altimmune, Inc. The stock&39;s last reported lowest price was 12. · Altimmune (NASDAQ: ALT) is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Compare Brokers Why Altimmune Stock Is Skyrocketing Today. (ALT) stock discussion in Yahoo Finance&39;s forum.
By utilizing the Company’s proprietary intranasal vaccine technology, it is expected that AdCOVID has the potential to activate multiple arms of the immune system as shown in a recent Phase 2 clinical study with NasoVAX, an influenza vaccine candidate based on the. 35 on Tuesday, in a 52-week range of . (ALT) stock price, news, historical charts, analyst ratings and financial information from WSJ. Share your opinion and gain insight from other stock traders and investors. ALT has fallen -.
Company’s recent per share price level of . Taylor Carmichael (TMFSaintCroix) at 6:40AM Author Bio. Find the latest analyst research for Altimmune, Inc. Taylor Carmichael is a. 58 percent from. That is because the . 2 days ago · Altimmune, Inc. · Shares of Altimmune were up 9.
is a clinical stage immunotherapeutic biotechnology company. 2 percent decrease since the beginning of the trading day. (ALT) stock quote, history, news and other vital information to help you with your stock trading and investing. · ALT | Complete Altimmune Inc. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. In fact, the stock has skyrocketed 433. The Investor Relations website contains information about Altimmune&39;s business for stockholders, potential investors, and financial analysts. Vaxart Both of these small-cap vaccine stocks are up big in.
8% so far this year against the industry’s decrease of 3. 61% on the day and +458. · Investors in Altimmune, Inc. Currently, the shares are at . Over the past year the S&P 500 has risen 14.
1% following the above announcement on Wednesday. 36% as of 2:23 PM on Monday, Nov 16. 33 as of the 8th of December ; that is -4. Get full conversations at Yahoo Finance. The average Altimmune stock price prediction forecasts a potential upside of 282. · Altimmune Inc. Altimmune Inc is a United States-based clinical-stage immunotherapeutic biotechnology company.
View real-time stock prices and stock quotes for a full financial overview. View the latest Altimmune Inc. · Better Coronavirus Stock: Altimmune vs. : News, information and stories for ALTIMMUNE, INC. Common Stock (ALT) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market altimmune stock activity data for altimmune stock US and global markets. 2 days ago · Altimmune hopes to begin a phase 1 study of AdCOVID in humans this month. 57 trading at .
50, predicting that the stock has a possible upside of 121. · (RTTNews) - Altimmune, Inc. 07% in the latest session and is positioned +38. and has now fallen 4 days in a row. ALT investment & stock information. 25% up on its price 12 months ago. 2 Wall Street analysts have issued ratings and price targets for Altimmune in the last 12 months.
A stock’s Dividend Uptrend rating is dependent on the company’s price-to-earnings (P/E) ratio to evaluate whether or not a stock’s dividend is likely to trend upward. 07% while the S&P 500 is higher by 1. Barron&39;s also provides information on historical stock ratings, target prices, company earnings, market valuation and more.
· View Altimmune, Inc. Altimmune Announces Closing of 2 Million Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters Option GlobeNewswire altimmune stock Jul:40PM. Get the latest Altimmune, Inc.
Stock Price: ALT (NasdaqGS) . 50 Call had some of the highest implied. View today&39;s stock price, news and analysis for Altimmune Inc. · Altimmune, Inc. InMode, Altimmune: 5 Top Stock Gainers for Tuesday.
If this early-stage study goes well, the biotech stock will likely make an even bigger step toward achieving Chikere&39;s. Their average twelve-month price target is . 13 on volume of 1,279,318 shares.
In addition, we are developing intranasal vaccine & therapeutic candidates for anthrax, influenza and COVID-19. The Altimmune, Inc. stock has performed in comparison to its peers in the industry, here’s what we find: ALT’s stock is -2.
00 per share in the over the last 12 months. · In last trading session, Altimmune, Inc. (Updated on Decem) Sell candidate sincePDF.
A high-level overview of Altimmune, Inc. 78 Million and is expected to release its quarterly earnings report on Novem. Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease and immune modulating therapies. Common Stock (ALT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. · Altimmune News: ALT Stock Skyrockets on Positive Flu Vaccine Data Nonetheless, any time altimmune stock investors are making a decision with regard to investing, investors should focus on far more than just news, this is especially the case in the highly speculative biotechnology space. 21% from the current ALT share price of . 08%) Wed,, 4:00PM EST Get the latest Altimmune detailed stock quotes, stock trade data, stock price info, and performance analysis, including Altimmune investment advice, charts, stats and more. stock downgraded from Hold/Accumulate to Sell Candidate after Friday trading session.
(ALT) shares are declining more than 8 percent on Monday morning, as the stock is in search of new support. 75 by. Altimmune stock was falling hard Monday on news that the company is selling additional stock to investors in a new offering. Altimmune is selling for under 12.
08% in the past 12 months, while Zoetis Inc Cl A (ZTS) is trading -0. More news for Altimmune altimmune stock Stock. (NASDAQ:ALT) saw 1,211,571 shares changing hands with its beta currently measuring 1. The consensus price target is . ALT, Altimmune Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines. 5:15 PM EDT. stock news by MarketWatch. Per the company,.
68% at ring of the bell on the day assigns it a market valuation of 6. stock price fell by -2. It is involved in the business of developing products that engage, stimulate and improve immune. Common Stock (ALT) at Nasdaq. IIROC Trading Resumption - ALT. · Altimmune Inc (ALT) stock is down -9. On average, Wall Street analysts predict that Altimmune&39;s share price could reach .
It focuses on the discovery and development of products to stimulate robust and durable immune responses. · Altimmune stock traded up over 19% to . ALT need to pay close attention to the stock based on moves in the options market lately. 44% on the last day (Friday, 11th Dec ) from . Our diverse pipeline includes treatments for NASH (ALT-801), chronic Hepatitis B, and conjugated immunostimulants for the treatment of cancer.
-> Universal studios stock quote
-> Nio stock quiet period